$ENSC entry PT 1.25-1.50 Target PTs 6-7 and higher

Ensysce Biosciences shares are trading higher after Zacks Small-Cap Research set a $23 valuation on the stock.

Ensysce Biosciences, Inc., a clinical-stage biotech company, engages in developing various prescription drugs. The company is developing tamper-proof opioids using Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. Its products treat severe pain and assist in preventing deaths caused by opioid abuse. The company is headquartered in La Jolla, California.